PMID- 17026798
OWN - NLM
STAT- MEDLINE
DCOM- 20070215
LR  - 20211203
IS  - 1558-7673 (Print)
IS  - 1558-7673 (Linking)
VI  - 5
IP  - 2
DP  - 2006 Sep
TI  - Current data with mammalian target of rapamycin inhibitors in advanced-stage 
      renal cell carcinoma.
PG  - 110-3
AB  - Mammalian target of rapamycin (mTOR) is the key regulator of cell growth and 
      proliferation. Alterations in the mTOR signaling pathway can lead to neoplastic 
      transformation and progression. The inhibition of mTOR blocks the progression of 
      the cell cycle from G1 to S phase, leading to cell growth arrest and apoptosis. 
      Thus, mTOR is a promising target for the treatment of human malignancies. 
      Rapamycin and its analogues, including temsirolimus, everolimus, and AP23573, 
      block the mTOR signaling pathway and induce a cellular state akin to starvation, 
      with significant antitumor activity in a variety of malignancies, including renal 
      cell carcinoma (RCC). Current data from ongoing clinical trials suggest that 
      mTOR-targeted therapy with rapamycin derivatives is well tolerated with 
      significant clinical activity in patients with advanced-stage RCC. Specifically, 
      temsirolimus as monotherapy has demonstrated improved progression-free and 
      overall survival in patients with poor-risk advanced-stage RCC. Everolimus has 
      also demonstrated promising antitumor activity in patients with metastatic RCC. 
      However, optimal dose, treatment schedule, selection of patients, and appropriate 
      combination strategies with other novel agents need to be defined for 
      mTOR-targeted therapies in the treatment of advanced-stage RCC.
FAU - Reddy, G Kesava
AU  - Reddy GK
AD  - CIG Media Group, LP, Dallas, TX, USA.
FAU - Mughal, Tariq I
AU  - Mughal TI
FAU - Rini, Brian I
AU  - Rini BI
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/metabolism/secondary
MH  - Clinical Trials as Topic
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/metabolism/pathology
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein Kinases/*drug effects
MH  - TOR Serine-Threonine Kinases
RF  - 23
EDAT- 2006/10/10 09:00
MHDA- 2007/02/16 09:00
CRDT- 2006/10/10 09:00
PHST- 2006/10/10 09:00 [pubmed]
PHST- 2007/02/16 09:00 [medline]
PHST- 2006/10/10 09:00 [entrez]
AID - S1558-7673(11)70173-2 [pii]
AID - 10.3816/cgc.2006.n.026 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2006 Sep;5(2):110-3. doi: 10.3816/cgc.2006.n.026.